Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches - Middle East Business News and Information
Number of patients reached in 2024 jumps 8% to 66 million.
In 2024, Boehringer Ingelheim in India, Middle East, Turkey and Africa (IMETA) region achieved net sales of EUR 855 million, reflecting a 17% increase compared to the previous year.
R&D investments rise to EUR 6.2 billion, 23.2% of group net sales.
Company prepares new product launches starting in 2025.
Dubai, United Arab Emirates: Boehringer Ingelheim today announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. Development of its current product pipeline is well on track, as the company prepares multiple new product launches, starting in 2025. Research & Development (R&D) investments rose to EUR 6.2 billion, or 23.2% of group net sales. Group net sales rose by 6.1%* to EUR 26.8 billion.
'As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal phase of high investments, to bring these new innovations to patients,' said Hubertus von Baumbach, Chairman of the Board of Managing Directors. 'It is important that we use every opportunity to bring these new treatments to patients as fast as possible – this is our number one priority.'
Strong Growth in IMETA:
In India, Middle East, Turkey, and Africa (IMETA) region, the company recorded net sales of 855 million EUR (2023: 732 million EUR), a 17% increase compared to the previous year.
Derek O'Leary, Regional Managing Director at Boehringer Ingelheim India, Middle East, Turkey and Africa (IMETA) said: 'Our strong performance in 2024 underscores our commitment to addressing unmet medical needs in both human and animal health. We will continue to work towards expanding access to innovative treatments for people and strengthen our efforts to safeguard animal health and well-being, impacting a greater number of lives. In partnerhip with our stakeholders, we are eager to build on this momentum in 2025 through further science-backed innovations tailored to the needs of both patients and animals.'
Human Pharma: investing in existing products and new launches
Human Pharma sales rose by 7.0%* to EUR 21.9 billion, led by the treatment of chronic kidney diseases, type 2 diabetes and heart failure, rose 14.6%* to EUR 8.4 billion. Treatments used for idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, grew 8.9%* to EUR 3.8 billion.
The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human Pharma R&D spending rose to EUR 5.7 billion, or 27.6% of the business unit's net sales.
'If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D,' said Frank Hübler, Member of the Board of Managing Directors with responsibility for Finance. 'With the innovations currently in our pipeline we will further increase investments in R&D in the years to come.'
After positive data from pivotal studies, the company is preparing multiple new product launches to advance care for patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis as well as the first orally administered, targeted therapy for previously treated HER2-mutated lung cancer patients.
Both treatments have been submitted to regulatory authorities globally and first launches in the US are anticipated in the second half of this year, pending approval.
Animal Health: rapid response against transboundary animal diseases
Animal Health sales rose 1.9%* to EUR 4.7 billion in 2024, mainly driven by Pet Parasiticides and Therapeutics, Poultry and Ruminant. The parasiticides continued to strengthen its position as the top-selling brand in the industry, growing 14.0%* to EUR 1.4 billion.
Last year, Boehringer Ingelheim supported livestock producers and governments by quickly providing vaccines and technical assistance for outbreaks of transboundary animal diseases (TADs), such as avian influenza, bluetongue virus and foot-and-mouth disease. These diseases pose a significant risk to animal health, impede global trade, and constrain food supply.
Sustainable Development:
Boehringer Ingelheim is on track in its target to become carbon neutral in its company operations by 2030. It increased global renewable electricity purchases to around 75% in 2024, primarily due to transitioning to renewable solutions at various sites, including Japan and China. A new biomass power plant was also commissioned at its Ingelheim site in Germany to boost on-site renewable energy generation to 95% of its energy needs.
As part of its global effort to stop rabies, the company provided 46 million rabies vaccine doses and supported vaccination campaigns in endemic countries. The 'Angels' initiative, which aims to optimize the quality of treatment in existing stroke centers, added over 1,000 organizations to the network. It is the largest stroke community in the world, now encompassing 237,000 healthcare professionals from more than 9,000 hospitals in 158 countries and has helped 19 million stroke patients to date.
Outlook:
The general trends and developments of the past year are expected to continue to impact 2025. The company expects a continued rise in the number of patients reached, and a slight year-on-year increase in net sales, adjusted for currency and extraordinary effects.
* sales growth numbers are adjusted for currency effects
**one-sided p-value from a z-test of the null hypothesis ORR ≤30%
Boehringer Ingelheim:
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
2 days ago
- Mid East Info
Wheat rise on short covering and weather woes, but fundamentals still lacking – Saxo Bank MENA - Middle East Business News and Information
Ole Hansen, Head of Commodity Strategy, Saxo Bank Wheat futures in Chicago surged to a two-month high on Wednesday, driven by adverse weather across key growing regions in the U.S., Europe, and Russia, alongside signs of robust export demand—particularly into North Africa. The rally, which comes ahead of the U.S. holiday, has been amplified by hedge funds reducing long-held short positions in both CBOT and Kansas HRW contracts. Images of combine harvesters stuck in muddy fields underscore the slow start to the U.S. winter wheat harvest. Persistent rains across the southern Plains—especially in Oklahoma and Kansas—have delayed progress. In Oklahoma, just 5% of the crop had been harvested by early June, down sharply from 44% last year and well below the five-year average of 23%. Nationwide, only 10% of the winter wheat crop has been harvested—the slowest pace since 2019—compared with the seasonal norm around 18%, according to USDA. Despite the harvest delays, early crop quality and yields have exceeded expectations. The USDA this week also lifted its spring wheat condition rating to 57% good or excellent, up from 53%, suggesting no immediate threat to overall production. On the charts, the most traded September and December CBOT wheat contracts have approached key trendline resistance, at USD 5.94 and USD 6.19 respectively, with last trades at USD 5.905 and USD 6.12. Elsewhere, weather challenges continue to unfold. In Russia, drought-hit regions such as Krasnodar and Rostov have declared emergencies, fuelling protective buying in Europe. In Western Europe, spring rains have improved crop conditions but delayed ripening and harvest, while also raising the risk of disease. In response, the benchmark Paris Milling Wheat contract recently broke back above EUR 200/ton, last trading near a one-month high around EUR 208. Whether these developments mark a sustainable bottom around USD 5 (CBOT wheat) remains to be seen. So far, the main bid has come from funds reducing bearish exposure. Hedge funds have maintained a net short in CBOT wheat for three consecutive years, and in Kansas HRW since August 2023. In the four weeks to June 10, managed money cut its CBOT net short by 26% to 94k contracts, while the Kansas net short was trimmed by just 7% to 75k. As per the charts above, additional price strength leading to an upside break may add further momentum to the rally, not necessarily due to price-friendly fundamentals, but first of all due to buying as wrong-footed longs scale back bearish bets. For the rally to become more sustainable, thereby signalling a low in the market following three years of weakness, the global production outlook needs to deteriorate further, so for now we view the rally as technically more than fundamentally driven.
Mid East Info
5 days ago
- Mid East Info
DoH and Boehringer Ingelheim Ink Strategic Partnership to Advance Life Science Innovation Across the Emirate
On the sidelines of a high-profile Abu Dhabi delegation visit to the USA Abu Dhabi, United Arab Emirates,June 2025: The Department of Health – Abu Dhabi DoH, the regulator of the healthcare sector in Abu Dhabi, signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim , one of the world's leading research-driven pharmaceutical companies. This strategic partnership aims to advance scientific research and innovation, foster groundbreaking research and development and cultivate an environment of scientific excellence, further cementing the Emirate as the MENA region's premier hub for healthcare, life sciences and innovation. In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at BI, the agreement was signed during BIO International Convention in Boston at the Abu Dhabi Pavilion by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at BI. Through this strategic partnership, the two parties seek to strengthen the Emirate's research ecosystem by facilitating access to and harnessing the capabilities of Boehringer Ingelheim's OpnME platform. Researchers, scientists and innovators across Abu Dhabi will be able to leverage the platform's cutting-edge data and resources to address critical biological challenges and accelerate scientific discovery. Through four flagship programmes, Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e) and opnTALENTS (o25), the platform empowers the research community with access to advanced compounds, collaborative opportunities, expert networks and support for emerging talent. OpnME connects visionary researchers to champion transformative, research-driven medical innovation for generations to come. In line with Abu Dhabi's vision to shape the future of healthcare, this partnership between DoH and BI enhances knowledge exchange and invests in local talent. It offers scientists a purpose-driven, globally connected environment to lead impactful research, further reinforcing the Emirate's commitment to transforming the regional healthcare ecosystem through science and technology. Dr. Asma Ibrahim Al Mannaei, the Executive Director of the Health Life Sciences Sector at DoH, said: 'Our partnership with Boehringer Ingelheim reflects our commitment to pioneering innovation and scientific research as parts of our efforts to advance health outcomes and improve the quality of life for communities around the world. We're empowering Abu Dhabi researchers with the opnMe platform, an open portal offering top-tier pharmaceutical compounds, fostering collaboration and safeguarding researchers' rights to their findings. This is about transforming our emirate into a global life sciences hub, speeding up breakthroughs, and building a healthier, resilient future for all. Ousama Alhaj, General Manager and Head of Human Pharma for Near East and UAE at Boehringer Ingelheim, said: 'At Boehringer Ingelheim, we are proud to partner with the Department of Health – Abu Dhabi (DoH) to empower the scientific community through our OpnMe platform. This collaboration reflects our shared commitment to advancing research and innovation in the region, fostering a culture of discovery, and ultimately improving patient outcomes. By providing access to our scientific resources, including advanced compounds, collaborative research opportunities, and expert networks, we aim to inspire new ideas and support the next generation of researchers in Abu Dhabi.' Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 14 to 21, delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions.
Mid East Info
11-06-2025
- Mid East Info
COT Report: Metals, energy demand offset by broad Ag selling
Ole Hansen, Head of Commodity Strategy, Saxo Bank In the latest reporting week to 3 June, the period saw the USD trade broadly weaker. Speculators nevertheless responded by reducing their overall short USD position versus the eight IMM FX futures contracts by 8%, to USD 12.2 billion. At the individual currency level, buying of EUR and MXN was more than offset by selling of JPY and CAD. Strong metals and energy demand offset by agriculture selling The reporting week to 3 June showed a major divergence in hedge funds' appetite for exposure—strong demand for energy and metals, both precious and industrial, was partly offset by broad net selling across the agriculture sector. Overall, the Bloomberg Commodity Index rose 0.4% during the week, with strong gains across both metals sectors being offset by a 3.4% loss in the agriculture sector, where all components except coffee suffered setbacks. At the individual commodity level, hedge funds concentrated their demand in WTI crude oil, gas oil, natural gas, gold, and silver. Meanwhile, the broad selling in agriculture was led by soybeans, corn, and sugar. Silver—which had yet to break the USD 35 resistance level as of last Tuesday—saw its net long rise by 36% to 45.4k contracts, just 4.3k contracts below the five-year high set in March. In contrast, fresh short selling reduced the platinum net long by 31% to 12.8k contracts, just before prices embarked on a fresh surge that resulted in a 12% rise since last Tuesday.
